Financial
Personal
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week
SEATTLE and VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the development and commercialization of cytisinicline for nicotine dependence,
To date, Achieve has successfully completed two Phase 3 clinical trials of cytisinicline in more than 1,600 subjects who smoke combustible cigarettes and one Phase 2 clinical trial for adults who vape nicotine e-cigarettes and desire to quit. Achieve expects to submit a New Drug Application (NDA) for cytisinicline as an aid to smoking cessation in the second quarter of 2025. Additionally, it expects to commence a single Phase 3 clinical trial of cytisinicline for nicotine e-cigarette or vaping cessation in the third quarter of 2025. Read More
